Researcher from the University of California, Berkeley have elucidated the key role of Treg cell expression of CXCR3 in promoting cancer progression, revealing the mechanism by which CXCR3 targeting Treg promotes anti-tumor CD8 + T cell activity, and emphasizing that CXCR3 + Treg is a therapeutic target for cancer immunotherapy [26]. Here, CD8A is linked to neoplasm.